21/09/2026
Aux HDN, notre priorité est d'assurer votre sécurité et celle de votre bébé. L'hiver est une période critique, où circulent de nombreux virus.
Voici comment protéger votre bébé contre l'un des plus dangereux : le VRS.
Sources :
▪ Santé publique France. Bulletin épidémiologique bronchiolite semaine 9. Saison 2022-2023
▪ Nirsevimab vs RSV preF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns Jabagi MJ et al, JAMA.2026;335(9):787-798.doi:10.1001/jama.2025.24082
▪ Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: a population-based retrospective cohort study Valtuille Z, Fafi I, Kaguelidou F et al. The Lancet Child & Adolescent Health, 2026; 10, 481-490
▪ Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth. Jasset OJ Am J Obstet Gynecol. 2025 Jun;232(6):554.e1-554.e15. doi:
10.1016/j.ajog.2024.10.053. Epub 2024 Nov 7. PMID: 39515450; PMCID: PMC12056162.
▪ Early impact of nirsevimab on ambulatory all-cause bronchiolitis: a prospective multicentric surveillance study in France Levy C et al.. J Pediatric Infect Dis Soc. 2024 May 23
▪ Effectiveness of nirsevimab against RSV bronchiolitis in paediatric ambulatory care : a test-negative casecontrol study. Lassoued Y, Levy C, Werner A, et al. Lancet Reg Health Eur 2024 Jul 23 ; 44 : 101007.
▪ Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France Paireau J, et al., September 2023-January 2024. Influenza Other Respir Viruses. 2024;18(6):e13311.
▪ Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study A Brault Lancet Child Adolesc Health 2024 Oct;8(10):721-729.
▪ Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants S.B. Drysdale, Ph.D. for the HARMONIE Study Group N Engl J Med 2023;389:2425-2435 VOL. 389 NO. 26
▪ Nirsevimab effectiveness on paediatric emergency visits for RSV bronchiolitis: a test-negative design study.
L Lenglart Eur J Pediatr 2025 Feb 1;184(2):171.
▪ 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Munro, A. P. S. Lancet Child Adolesc Health 2025 Jun;9(6):404-412.
▪ Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis D Sumsuzzman Lancet Child Adolesc Health 2025 Jun;9(6):393-403.
▪ Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial EAF Simões MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group 2025 Feb 1;145(2):157-167.
▪ MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. Hammitt LL et al. N Engl J Med. 2022 Mar 3;386(9):837-846.